Guardian Pharmacy Services IncGRDN
Price$40.84Intrinsic value$39.124% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $39.12median of 6 methods · middle span $26-$93based on filings through 30 Jun 2026
Market Price $40.84Price as of 1 Oct 2026
Margin of Safety -4.2%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 23.4% (near-term consensus, capped) · years 2–5: 11.4%/yr (balance of the path).13.7% per year
Years 6–10: glide to demonstrated growth own history 31.2%, capped at 20%
Per-year rates
Yr 611.9%Yr 712.3%Yr 812.8%Yr 913.3%Yr 1013.7%
11.4% → 13.7%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1112.6%Yr 1211.6%Yr 1310.5%Yr 149.4%Yr 158.4%Yr 167.3%Yr 176.2%Yr 185.1%Yr 194.1%Yr 203.0%
13.7% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)31.2%
Discount rate (cost of equity) 6.8%
Volatility vs market (adjusted beta)0.41

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetGuardian Pharmacy Services IncGRDNHealth Care
Valuation
P/E—
P/S2.0×
P/B11.1×
EV / Revenue1.9×
EV / EBITDA23.2×
Profitability
Gross margin21.6%
Operating margin5.0%
Net margin4.5%
FCF margin6.4%
Returns
ROE25.6%
ROA14.9%
ROIC33.5%
Growth
Revenue growth (YoY)19.1%
5-yr fwd EPS growth13.7%
Financial strength
Debt / Equity0.11×
Current ratio1.65×
Altman Z-Score13.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.